(Q21710731)

PubMed

PubMed publication ID

16735148

American Journal of Medicine

7 February 2023

language of work or name

English

0 references

publication date

June 2006

0 references

published in

0 references

volume

119

0 references

issue

6

0 references

page(s)

S29-S36

0 references

cites work

Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Metallo-beta-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Emerging epidemic of metallo-beta-lactamase-mediated resistances.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Antipseudomonal antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Antimicrobial resistance in intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Control of antimicrobial resistance in the health care system

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Minimizing potential resistance: the molecular view

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

The impact of antimicrobial resistance on health and economic outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Trends in antimicrobial drug development: implications for the future

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Overview of nosocomial infections caused by gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Emergence of resistance in Pseudomonas aeruginosa and Acinetobacter species after the use of antimicrobials for burned patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Clinical problems posed by multiresistant nonfermenting gram-negative pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001)

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Bacteraemia in adults due to glucose non-fermentative Gram-negative bacilli other than P. aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Transferable imipenem resistance in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Aminoglycoside resistance in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Infection control in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Economic impact of antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Antimicrobial resistance determinants and future control

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Severe Pseudomonas aeruginosa infections. Tackling the conundrum of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021

Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FJ.AMJMED.2006.03.014

7 January 2021